Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06479187 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

StatusActive, Not Recruiting
PhasePhase 4
Started2024-06-30
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 5, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-11-04
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v2
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 2 of 2 sites
2025-02-03
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Study sites1→2
2024-06-24
Original filing
The goal of this clinical trial is to learn if serial PSMA-PET/CT scans can be used to monitor response to therapy in metastatic hormone sensitive prostate cancer and can be potentially used to optimize future treatment approaches. The main questions it aims to answer are: What is the proportion of men with residual PSMA-avid disease on PET/CT scans after 6 months of treatment for metastatic hormone sensitive prostate cancer? Do the findings on PSMA-PET/CT scans after 6 months of treatment for metastatic hormone sensitive prostate cancer correlate with other markers of disease status, like PSA? Participants will: Receive standard of care treatment for metastatic hormone sensitive prostate cancer Undergo a PSMA-PET/CT scan before starting treatment Undergo a PSMA-PET/CT scan after 6 months of treatment Have a chart review every 3 months for 1 year after the 6 month PSMA-PET/CT scan
Trial Details
NCT Number NCT06479187
Lead Sponsor Brigham and Women's Hospital
Collaborators: Dana-Farber Cancer Institute, Blue Earth Diagnostics
Conditions Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Enrollment 20 participants
Start Date 2024-06-30
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-20 (estimated)
Updated on ClinicalTrials.gov 2025-11-05